Background: Only a few reports have currently studied the efficacy of dutasteride in patients with small benign prostatic hyperplasia (BPH). We investigated the efficacy of dutasteride on reducing lower urinary tract symptoms among them.
Materials and methods: A total of 81 patients with BPH who completed 52weeks of 0.5?mg dutasteride treatment were enrolled. Each patient filled out the International Prostatic Symptom Score (IPSS) and overactive bladder symptom score (OABSS) at baseline and at the 6- and 12-month follow-up visits. Total testosterone, prostate-specific antigen, adenoma/prostate volume (PV), uroflowmetry analysis, and postvoid residual volume were evaluated at baseline and at the 12-month follow-up visit. The enrolled patients were divided into 2 groups according to PV at baseline. The groups were as follows: Group A (PV ≥ 30 mL) and Group B (PV < 30 mL).
Results: Groups A and B had mean PVs of 52.1 and 23.6 mL and mean IPSS scores of 16.7 and 14.4, respectively. Group A had significantly higher OABSS and prostate-specific antigen levels at baseline than Group B, while no significant differences in any other baseline characteristics was observed. After dutasteride treatment, adenoma volume and PV decreased significantly, while testosterone level showed a significant increase in both groups. Group A showed significant improvements in the total IPSS, voiding and storage subscore of the IPSS, OABSS, maximum flow rate, and postvoid residual volume. Group B, on the other hand, also showed significant improvements only in the total IPSS, voiding subscore of the IPSS, and maximum flow rate.
Conclusions: The present study suggests a possible beneficial effect of dutasteride treatment on the reduction of lower urinary tract symptoms in patients with small and large BPH. However, the effectiveness of dutasteride was limited compared to patients with large BPH (PV ≥ 30 mL).
Acknowledgments
None.
Statement of ethics
The study was conducted in accordance with the Declaration of Helsinki and its amendments and was approved by our hospital ethics committee. Written informed consent was obtained from all participants prior to the start of this study.
Conflict of interest statement
No conflict of interest has been declared by the author.
Funding source
The authors received no financial support for the research, authorship, and/or publication of this article.
Author contributions
All authors contributed equally in this study.
Data availability
The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.
| [1] |
Roehrborn CG, Boyle P, Nickel JC, et al. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002; 60 (3):434-441.
|
| [2] |
Debruyne F, Barkin J, Van Erps P, Reis M, Tammela TLJ, Roehrborn C. Efficacy and safety of long-term treatment with the dual 5α-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 2004; 46 (4):488-495.
|
| [3] |
Tsukamoto T, Endo Y, Narita M. Efficacy and safety of dutasteride in Japanese men with benign prostatic hyperplasia. Int J Urol 2009; 16 (9):745-750.
|
| [4] |
Shigehara K, Koh E, Sakamoto J, et al. Effects of dutasteride on lower urinary tract symptoms and general health in men with benign prostatic hypertroplasia and hypogonadism: A prospective study. Aging Male 2014; 17 (1):51-56.
|
| [5] |
Homma Y, Kawabe K, Tsukamoto T, et al. Estimate criteria for diagnosis and severity in benign prostatic hyperplasia. Int J Urol 1996; 3 (4):261-266.
|
| [6] |
Boyle P, Gould AL, Roehrborn CG. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials. Urology 1996; 48 (3):398-405.
|
| [7] |
Roehrborn CG, Marks LS, Fenter T, et al. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology 2004; 63 (4):709-715.
|
| [8] |
Matsukawa Y, Gotoh M, Kato M, Funahashi Y, Narita M, Mitsui K. Effects of dutasteride on storage and voiding symptoms in male patients with lower urinary tract symptoms as a result of benign prostatic obstruction: The 1-year outcomes from a prospective urodynamic study. Int J Urol 2014; 21 (8):826-830.
|
| [9] |
Roehrborn CG, Nickel JC, Andriole GL, et al. Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: Secondary analysis of the reduction by dutasteride of prostate cancer events (REDUCE) trial’. Urology 2011; 78 (3):641-646.
|
| [10] |
Hashimoto M, Shimizu N, Sugimoto K, et al. Efficacy of adding dutasteride to (-blocker therapy treated benign prostatic hyperplasia patients with small volume prostate (<30 mL). Low Urin Tract Symptoms 2017; 9 (3):157-160.
|
| [11] |
Tsukamoto T, Endo Y, Narita M. Assessment of recommended dose of dutasteride on Japanese men with benign prostatic hyperplasia: Arandomized, double-blind, placebo-controlled, parallel-group, dose response study. Hinyokika Kiyo 2009; 55 (4):209-214.
|
| [12] |
Rittmaster R, Hahn RG, Ray P, Shannon JB, Wurzel R. Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer. Urology 2008; 72 (4):808-812.
|
| [13] |
Shigehara K, Namiki M. Late-onset hypogonadism syndrome and lower urinary tract symptoms. Korean J Urol 2011; 52 (10):657-663.
|
| [14] |
Wada N, Hashidume K, Tamaki G, et al. Add-on effect of dutasteride in patients with benign prostatic hyperplasia treated with alpha blocker: Its effect on overactive bladder. Hinyokika Kiyo 2012; 58 (9):475-480.
|
| [15] |
Shigehara K, Miyagi T, Nakashima T, et al. Effects of dutasteride on lower urinary tract symptoms: A prospective analysis based on changes in testosterone/dihydrotestosterone levels and total prostatic volume reduction. Aging Male 2016; 19 (2):128-133.
|
PDF
(151KB)
